References
- 1. Bhat KS, Priya R, Krishnan L, Kanungo R. Elizabethkingia meningoseptica bacteremia in a neonate: A case report and mini-review of the literature. J Curr Res Sci Med. 2016;2:42-5.
- 2. Oren A, da Costa MS, Garrity GM, et al. Proposal to include the rank of phylum in the international code of nomenclature of prokaryotes. Int J Syst Evol Microbiol. 2015;65:4284–7.
- 3. Kim KK, Kim MK, Lim JH, Park HY, Lee ST. Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov. Int J Syst Evol Microbiol. 2005;55(Pt 3):1287–93.
- 4. Breurec S, Criscuolo A, Diancourt L, et al. Genomic epidemiology and global diversity of the emerging bacterial pathogen Elizabethkingia anophelis. Sci Rep. 2016, 6:30379.
- 5. Chen S, Soehnlen M, Downes FP, Walker ED. Insights from the draft genome into the pathogenicity of a clinical isolate of Elizabethkingia meningoseptica Em3. Stand Genom Sci. 2017;12:56.
- 6. Jean SS, Lee WS, Chen FL, Ou TY, Hsueh PR. Elizabethkingia meningoseptica: an important emerging pathogen causing healthcare-associated infections. J Hosp Infect. 2014;86(4):244–9.
- 7. Pereira GH, Garcia DO, Abboud CS, Barbosa VLB, da PSL S. Nosocomial infections caused by Elizabethkingia meningoseptica: an emergent pathogen. Braz J Infect Dis. 2013;17:606–9.
- 8. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- 9. Eriksen HB, Gumpert H, Faurholt CH, Westh H. Determination of Elizabethkingia Diversity by MALDI-TOF Mass Spectrometry and Whole-Genome Sequencing. Emerg Infect Dis. 2017;23(2):320-3.
- 10. Hsu MS, Liao CH, Huang YT, et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999–2006. Eur J Clin Microbiol Infect Dis. 2011;30(10):1271–8.
- 11. Lin PY, Chen HL, Huang CT, Su LH, Chiu CH. Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacterium meningosepticum bacteraemia. Int J Antimicrob Agents. 2010;36:436–40.
- 12. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis for the ESCMID Study Group for Infections of the Brain (ESGIB). Clin Microbiol Infect. 2016;22:S37-S62.
- 13. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for Bacterial Meningitis. Clin Infect Dis. 2004;39:1267-84.
- 14. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467–92.
- 15. Hsu MS, Liao CH, Huang YT, et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999–2006. Eur J Clin Microbiol Infect Dis. 2011;30(10):1271–8.
- 16. Ceyhan M, Celik M. Elizabethkingia meningosepticum (Chryseobacterium meningosepticum) Infections in Children. Int J Pediatr. 2011:215-37.
- 17. Shah Z, Soodhana D, Kalathia M, Parikh Y. Elizabethkingia meningoseptica: an emerging threat. Int J Contemp Pediatr. 2017;4(5):1909-10.
- 18. Kavuncuoglu S, Gursoy S, Turel O, Aldemir EY, Hosaf E. Neonatal bacterial meningitis in Turkey: epidemiology, risk factors, and prognosis. J Infect Dev Ctries. 2013;7(2):73–81.
- 19. Lin PY, Chu C, Su LH, Huang CT, Chang WY, Chiu CH. Clinical and microbiological analysis of bloodstream infections caused by Chryseobacterium meningo-septicum in nonneonatal patients. J Clin Microbiol. 2004;42(7):3353–5.
- 20. Shinha T, Ahuja R. Bacteremia due to Elizabethkingia meningoseptica. IDcases. 2015;2(1):13-5.
- 21. Issack MI, Neetoo Y. An outbreak of Elizabethkingia meningoseptica neonatal meningitis in Mauritius. J Infect Dev Ctries. 2011;5(12):834–39.
- 22. Huang YC, Lin YT, Wang FD. Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia. Int J Antimicrob Agents. 2018;51(1):47-51.
- 23. Vincent JL, Bassetti M, Francois B, et al. Advances in antibiotic therapy in the critically ill. Crit Care. 2016; 20:133.
- 24. Neuner EA, Ahrens CL, Groszek JJ, et al. Use of therapeutic drug monitoring to treat Elizabethkingia meningoseptica meningitis and bacteraemia in an adult. J Antimicrob Chemother. 2012;67:1558–60.
- 25. Newby BD, Timberlake KE, Lepp LM, Mihic T, Dersch-Mills DA. Levofloxacin Use in the Neonate: A Case Series. JPPT. 2017;22(4):304-13.
- 26. Bruun B, Tversrupjensen E, Lundstrom K, Andersen GE. The C meningosepticum infection in a Neonatal ward. Eur J Clin Microbiol Infect Dis. 1989;816:509-14.
- 27. Bloch KC, Nadarajah R, Jacobs R. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltimore), 1997;76: 30-41.